SUBSCRIBE
SUBSCRIBE
Tyler Patchen

Tyler Patchen

Freelance Writer

Tyler is a journalist with over six years of experience in the world of business journalism. He started his career with the Birmingham Business Journal in Birmingham, Alabama writing about health care, technology, sports business and education. He previously worked as a reporter for Endpoints News and for BioSpace, covering biopharma business and manufacturing. Tyler currently lives in Birmingham, Alabama and holds interests in reading, golf and is also a passionate sports fan. You can reach him at tpatchen94@gmail.com.

Sangamo's headquarters in Silicon Valley
Drug Development
Despite Late-Stage Hemophilia Win, Sangamo Remains in Do-or-Die Situation
Sangamo and Pfizer’s hemophilia A gene therapy candidate scored a Phase III victory last week. However, with the genomic medicine company soon to run out of cash, Sangamo’s short-term prospects look bleak but not unsalvageable, analysts say.
July 31, 2024
 · 
3 min read
 · 
Tyler Patchen
Pictured: Photo illustration of hundred dollar bill and graph
Earnings
Pfizer, Merck Beat Wall Street Expectations Amid Strong Biopharma Q2 Earnings Season
Second-quarter revenues were better than analysts expected as Merck reported 16% growth for its blockbuster cancer treatment Keytruda, while Pfizer benefited from its ongoing cost-cutting efforts and sales of its COVID-19 antiviral Paxlovid.
July 30, 2024
 · 
2 min read
 · 
Tyler Patchen
External view of Boehringer Ingelheim's headquarters in Silicon Valley
Deals
Boehringer Buys Nerio Therapeutics for $1.3B to Boost Immuno-Oncology Pipeline
Under the deal announced Monday with the California biotech, German pharma Boehringer Ingelheim is gaining access to novel immune checkpoint inhibitors designed to activate the immune system to fight cancer cells.
July 29, 2024
 · 
2 min read
 · 
Tyler Patchen
Pictured: Collage of a dragon, congress, and money
BIOSECURE Act
WuXi AppTec Hit With Slight Drop in US Revenue as Threat of BIOSECURE Act Looms
With the BIOSECURE Act likely to be voted on in Congress this year, WuXi AppTec’s U.S. revenue dropped 1.2% in the first half of 2024 while the Chinese company increased its lobbying efforts.
July 29, 2024
 · 
2 min read
 · 
Tyler Patchen
The EMA's former headquarters in London
Regulatory
EU Regulatory Panel Recommends Against Approval of Eisai, Biogen’s Leqembi for Alzheimer’s
The European Medicines Agency’s Committee for Medicinal Products for Human Use found that Leqembi’s benefits do not outweigh the risks of severe side effects associated with the treatment.
July 26, 2024
 · 
2 min read
 · 
Tyler Patchen
AbbVie's office in South San Francisco, California
Earnings
Despite Near 30% Drop in Humira Sales, AbbVie Beats Wall Street’s Q2 Revenue Expectations
While Humira sales were impacted by cheaper biosimilars, AbbVie reported in its second-quarter earnings results Thursday that revenues jumped nearly 45% for Skyrizi and almost 56% for Rinvoq year over year, respectively.
July 25, 2024
 · 
2 min read
 · 
Tyler Patchen
Illustration of two hands about to shake with Moderna and Merck buildings in the background
Deals
Should Merck Buy Out Moderna on Keytruda–Cancer Vaccine Partnership?
A longtime biopharma exec and Moderna shareholder argues in an anonymous email to the companies’ CFOs that they have a fiduciary responsibility to close the deal. Analysts say the proposal is interesting but “too simplistic.”
July 24, 2024
 · 
9 min read
 · 
Jef Akst
Pictured: Nasdaq headquarters in New York/iStock,
Business
Updated: Artiva’s IPO Jumps to $167M
Cell therapy biotech Artiva Biotherapeutics plans to use the funds raised to support the development of its AlloNK therapy for systemic lupus erythematosus.
July 19, 2024
 · 
2 min read
 · 
Tyler Patchen
Novartis' office building in Marburg, Germany
Earnings
Despite Layoff Announcements, Novartis Beats Q2 Expectations
Novartis’ second-quarter earnings, announced Thursday, show strong performance of its blockbuster drugs, prompting the company to raise its year-end guidance.
July 18, 2024
 · 
2 min read
 · 
Tyler Patchen
Pictured: Healthcare worker conducting an eye exam
Drug Development
4DMT Unveils More Positive Data for Wet AMD Candidate
Mid-stage data for 4D Molecular Therapeutics’ wet AMD drug 4D-150 show improvements in visual acuity, reduced injection rate and encouraging safety data.

July 17, 2024
 · 
2 min read
 · 
Tyler Patchen
Colorful Pills scattered from white plastic pill bottle on blue background.
Obesity
Pfizer’s Once-Daily Weight Loss Pill—Good Play or Bad?
After nixing a twice-daily version of its oral GLP-1 agonist, Pfizer is hoping to break into the weight-loss space with a once-daily version, but experts question its outlook.
July 17, 2024
 · 
4 min read
 · 
Tyler Patchen
Podcast
Pfizer’s Oral GLP-1 Push, Lilly Vs. Novo and PBMs Under Pressure
Pfizer selects its candidate for the oral GLP-1 race as Eli Lilly strives to overtake Novo Nordisk in the injectable weight-loss drug space. Meanwhile, pressure builds to reduce drug prices in the U.S.
July 17, 2024
 · 
1 min read
 · 
Heather McKenzie
Pictured: Photo illustration of hundred dollar bill and graph
Business
Cardurion Raises $260M to Advance Cardiovascular Assets
Backed by Bain Capital, Cardurion Pharmaceuticals will use the Series B funds to advance two assets for heart failure and other cardiovascular conditions.
July 16, 2024
 · 
1 min read
 · 
Tyler Patchen
Pictured: Wall sign of the Novo Nordisk Foundation and Novo Holdings in Denmark
Funding
Novo Holdings Leads $100M Raise for Asceneuron’s Alzheimer’s Push
Asceneuron, which develops small molecules targeting tau protein aggregation, plans to use the funds to advance its Alzheimer’s disease asset into Phase II.
July 16, 2024
 · 
1 min read
 · 
Tyler Patchen
Lilly and injector pens
Weight loss
Will Eli Lilly Overtake Novo Nordisk in Weight-Loss Drug Race?  
Some analysts say so, and a recent study suggested Lilly’s tirzepatide beat Novo’s semaglutide at inducing weight loss, but there are other factors in the market race. 
July 16, 2024
 · 
4 min read
 · 
Tyler Patchen
Load More